Cilostazol for the treatment of distal symmetrical polyneuropathy in diabetes mellitus: Where do we stand?

IF 2.9 3区医学 Q3 ENDOCRINOLOGY & METABOLISM

Journal of diabetes and its complications Pub Date : 2024-11-07 DOI:10.1016/j.jdiacomp.2024.108905

Dimitrios Pantazopoulos , Evanthia Gouveri , Manfredi Rizzo , Nikolaos Papanas

{"title":"Cilostazol for the treatment of distal symmetrical polyneuropathy in diabetes mellitus: Where do we stand?","authors":"Dimitrios Pantazopoulos , Evanthia Gouveri , Manfredi Rizzo , Nikolaos Papanas","doi":"10.1016/j.jdiacomp.2024.108905","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Diabetic Neuropathy (DN) is one of the most frequent chronic complications of diabetes mellitus. Its commonest form, distal symmetrical polyneuropathy (DSPN), is characterised by slowly progressing length-dependent nerve damage in the lower limbs, increasing the risk of foot ulcerations and leading to symptoms like tingling, pain, or numbness.</div></div><div><h3>Aim</h3><div>The aim of this review was to discuss the utility of cilostazol, a phosphodiesterase inhibitor with known antiplatelet, vasodilatory, anti-inflammation properties, in the treatment of DSPN.</div></div><div><h3>Results</h3><div>Preclinical studies in animals have demonstrated the ability of cilostazol to improve nerve function and to protect from peripheral nerve disruption and central sensitisation. However, clinical trials in humans are very sparse and have so far not been encouraging.</div></div><div><h3>Conclusions</h3><div>Further research is needed to fully understand the mechanisms and potential efficacy of cilostazol in treating DSPN.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"38 12","pages":"Article 108905"},"PeriodicalIF":2.9000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of diabetes and its complications","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1056872724002319","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Diabetic Neuropathy (DN) is one of the most frequent chronic complications of diabetes mellitus. Its commonest form, distal symmetrical polyneuropathy (DSPN), is characterised by slowly progressing length-dependent nerve damage in the lower limbs, increasing the risk of foot ulcerations and leading to symptoms like tingling, pain, or numbness.

Aim

The aim of this review was to discuss the utility of cilostazol, a phosphodiesterase inhibitor with known antiplatelet, vasodilatory, anti-inflammation properties, in the treatment of DSPN.

Results

Preclinical studies in animals have demonstrated the ability of cilostazol to improve nerve function and to protect from peripheral nerve disruption and central sensitisation. However, clinical trials in humans are very sparse and have so far not been encouraging.

Conclusions

Further research is needed to fully understand the mechanisms and potential efficacy of cilostazol in treating DSPN.

查看原文本刊更多论文

西洛他唑治疗糖尿病远端对称性多发性神经病变：现状如何？

简介：糖尿病神经病变（DN）是糖尿病最常见的慢性并发症之一：糖尿病神经病变（DN）是糖尿病最常见的慢性并发症之一。其最常见的形式是远端对称性多发性神经病变（DSPN），其特点是下肢神经损伤呈缓慢进展的长度依赖性，增加了足部溃疡的风险，并导致刺痛、疼痛或麻木等症状。目的：本综述旨在讨论西洛他唑在治疗 DSPN 中的效用，西洛他唑是一种磷酸二酯酶抑制剂，具有抗血小板、血管扩张和抗炎特性：在动物身上进行的临床前研究表明，西洛他唑能够改善神经功能，防止外周神经损伤和中枢敏感化。然而，在人体中进行的临床试验非常稀少，迄今为止并不令人鼓舞：要全面了解西洛他唑治疗 DSPN 的机制和潜在疗效，还需要进一步的研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of diabetes and its complications 医学-内分泌学与代谢

CiteScore

5.90

自引率

3.30%

发文量

153

审稿时长

16 days

期刊介绍： Journal of Diabetes and Its Complications (JDC) is a journal for health care practitioners and researchers, that publishes original research about the pathogenesis, diagnosis and management of diabetes mellitus and its complications. JDC also publishes articles on physiological and molecular aspects of glucose homeostasis. The primary purpose of JDC is to act as a source of information usable by diabetes practitioners and researchers to increase their knowledge about mechanisms of diabetes and complications development, and promote better management of people with diabetes who are at risk for those complications. Manuscripts submitted to JDC can report any aspect of basic, translational or clinical research as well as epidemiology. Topics can range broadly from early prediabetes to late-stage complicated diabetes. Topics relevant to basic/translational reports include pancreatic islet dysfunction and insulin resistance, altered adipose tissue function in diabetes, altered neuronal control of glucose homeostasis and mechanisms of drug action. Topics relevant to diabetic complications include diabetic retinopathy, neuropathy and nephropathy; peripheral vascular disease and coronary heart disease; gastrointestinal disorders, renal failure and impotence; and hypertension and hyperlipidemia.